Rinad Beidas, PhD, director of the Penn Medicine Nudge Unit, has been named an associate editor of the journal Implementation Science. Focusing on the implementation of evidence gleaned from research into healthcare practice, Implementation Science is the flagship journal for the field with more than 2 million direct downloads each year. Beidas, who is also founding director of the Penn Implementation Science Center at the Leonard Davis Institute of Health Economics, associate director of the Penn Center for Health Incentives and Behavioral Economics, and an associate professor of Psychiatry, Medical Ethics and Health Policy, and Medicine, has published more than 200 papers in the implementation science field. Her work focuses on leveraging insights from behavioral economics and implementation science to make it easier for clinicians, leaders, and organizations to use best practices to improve the quality and equity of care and enhance health outcomes.
Yogesh Goyal, PhD, a postdoctoral researcher in Genetics and Bioengineering, has been selected as a 2021 STAT Wunderkind, which honors the “next generation of scientific superstars.” Goyal’s research is centered around developing novel mathematical and experimental frameworks to study how a rare subpopulation of cancer cells are able to survive drug therapy and develop resistance, resulting in relapse in patients. In particular, his work provides a view of different paths that single cancer cells take when becoming resistant, at unprecedented resolution and scale. This research aims to help devise novel therapeutic strategies to combat the challenge of drug resistance in cancer.
Sarah Tishkoff, PhD, the David and Lyn Silfen University Professor in Genetics and Biology, and an international group of collaborators has been awarded $2.7 million from the Chan Zuckerberg Initiative’s Donor Advised Fund. Hers is one of 16 new projects funded by the Initiative that will provide insights into how genetic ancestry influences health and disease at the level of our cells. Tishkoff and collaborators will study gene expression and epigenetic variation in African immigrant populations in Philadelphia, Detroit, and Belgium, as well as populations from Morocco and Tanzania. This project provides a unique opportunity to distinguish how genetics and environment impact gene expression and immune response in each of these populations, increasing the understanding of variable risk for multiple diseases.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System (UPHS) and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $580 million awarded in the 2023 fiscal year. Home to a proud history of “firsts,” Penn Medicine teams have pioneered discoveries that have shaped modern medicine, including CAR T cell therapy for cancer and the Nobel Prize-winning mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System cares for patients in facilities and their homes stretching from the Susquehanna River in Pennsylvania to the New Jersey shore. UPHS facilities include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Doylestown Health, Lancaster General Health, Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, chartered in 1751. Additional facilities and enterprises include Penn Medicine at Home, GSPP Rehabilitation, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.9 billion enterprise powered by nearly 49,000 talented faculty and staff.